DuPont’s nutrition and bioscience business may be up for sale and Amsterdam’s Royal DSM may want to buy it, according to a report from Bloomberg.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The business could be valued at $25 billion, people who asked not to be identified told Bloomberg.
The specialty chemicals maker has been considering the sale or spinoff of its nutrition business, and has been in the process of selecting advisers to sort out offers for the division for some time, according to confidential sources.
In August, Bloomberg said that DuPont wanted to rid itself of the arm, and may be looking into a Reverse Morris Trust, a tax-free merger, as well.
Shares of DuPont fell 1.41% to $72.50 on Monday.
By Cherella Cox Owoyelu
Source: The Street
Polyethylene (PE) buyers face significant increases in the early stages of July discussions, although retroactive business means that final numbers will not be settled for some weeks. The high level […]
BP is selling its remaining standalone petrochemicals businesses to Ineos for $5 billion (£4 billion), as part of a reorganisation aimed at meeting the challenge of a transition to cleaner […]
OMV (Vienna, Austria) says its second-quarter 2020 ethylene/propylene net margin has fallen to €393/metric ton ($445), down from €475/metric ton in the prior-year quarter and €459/metric ton in the first […]
